国内最大級の歯科向け情報サイト WHITE CROSSへアクセスしようとしています。


WHITE CROSSは歯科・医療関係者に向けて、良質な歯科医療情報を提供することを目的とした会員制サイトです。

WHITE CROSSは歯科医師の3人に1人が利用する、国内最大級の歯科専門情報サイトです。歯科医師や歯科衛生士、歯科技工士をはじめ、医療関係者の皆様へ最新の歯科医療臨床・経営、ニュース、セミナー情報などを配信しています。

心不全・駆出率低下患者における腎機能悪化の実践的管理法。フランス心臓病学会心不全ワーキンググループと集学的専門家パネルからの声明 | 日本語AI翻訳でPubMed論文検索


PubMedの提供する医学論文データベースを日本語で検索できます。AI(Deep Learning)を活用した機械翻訳エンジンにより、精度高く日本語へ翻訳された論文をご参照いただけます。
Arch Cardiovasc Dis.2020 Jul;S1875-2136(20)30129-7. doi: 10.1016/j.acvd.2020.03.018.Epub 2020-07-10.


Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.

  • Nathan Mewton
  • Nicolas Girerd
  • Jean-Jacques Boffa
  • Cécile Courivaud
  • Richard Isnard
  • Laurent Juillard
  • Nicolas Lamblin
  • Matthieu Legrand
  • Damien Logeart
  • Christophe Mariat
  • Edith Meune
  • Pierre Sabouret
  • Laurent Sebbag
  • Patrick Rossignol
PMID: 32660835 DOI: 10.1016/j.acvd.2020.03.018.



Renal function is often affected in patients with chronic heart failure with reduced ejection fraction (HFrEF). The complex interplay between heart and renal dysfunction makes renal function and potassium monitoring mandatory. Renin-angiotensin-aldosterone system (RAAS) blockers are a life-saving treatment for patients with HFrEF, regardless of worsening renal function. Uptitration to the maximum-tolerated dose should be a constant goal. This simple fact is all too often forgotten (only 30% of patients with heart failure receive the target dosage of RAAS blockers), and the RAAS blocker effect on renal function is sometimes misunderstood. RAAS blockers are not nephrotoxic drugs as they only have a functional effect on renal function. In many routine clinical cases, RAAS blockers are withheld or stopped because of this misunderstanding, combined with suboptimal assessment of the clinical situation and underestimation of the life-saving effect of RAAS blockers despite worsening renal function. In this expert panel, which includes heart failure specialists, geriatricians and nephrologists, we propose therapeutic management algorithms for worsening renal function for physicians in charge of outpatients with chronic heart failure. Firstly, the essential variables to take into consideration before changing treatment are the presence of concomitant disorders that could alter renal function status (e.g. infection, diarrhoea, hyperthermia), congestion/dehydration status, blood pressure and intake of nephrotoxic drugs. Secondly, physicians are invited to adapt medication according to four clinical scenarios (patient with congestion, dehydration, hypotension or hyperkalaemia). Close biological monitoring after treatment modification is mandatory. We believe that this practical clinically minded management algorithm can help to optimize HFrEF treatment in routine clinical practice.

Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.